- Home
- RNXT vs IGC Comparison
RNXT vs IGC Comparison
Compare RNXT & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNXT
- IGC
- Stock Information
- Founded
- RNXT 2012
- IGC 2005
- Country
- RNXT United States
- IGC United States
- Employees
- RNXT N/A
- IGC N/A
- Industry
- RNXT Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- RNXT Health Care
- IGC Health Care
- Exchange
- RNXT Nasdaq
- IGC Nasdaq
- Market Cap
- RNXT 44.0M
- IGC 39.8M
- IPO Year
- RNXT 2021
- IGC N/A
- Fundamental
- Price
- RNXT $1.11
- IGC $0.40
- Analyst Decision
- RNXT Strong Buy
- IGC Strong Buy
- Analyst Count
- RNXT 2
- IGC 2
- Target Price
- RNXT $7.50
- IGC $4.00
- AVG Volume (30 Days)
- RNXT 552.5K
- IGC 905.0K
- Earning Date
- RNXT 11-13-2025
- IGC 11-14-2025
- Dividend Yield
- RNXT N/A
- IGC N/A
- EPS Growth
- RNXT N/A
- IGC N/A
- EPS
- RNXT N/A
- IGC N/A
- Revenue
- RNXT $662,000.00
- IGC $1,327,000.00
- Revenue This Year
- RNXT $2,895.35
- IGC $3.54
- Revenue Next Year
- RNXT $313.04
- IGC $15.12
- P/E Ratio
- RNXT N/A
- IGC N/A
- Revenue Growth
- RNXT N/A
- IGC 24.95
- 52 Week Low
- RNXT $0.75
- IGC $0.25
- 52 Week High
- RNXT $1.69
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- RNXT 46.69
- IGC 46.89
- Support Level
- RNXT $0.98
- IGC $0.38
- Resistance Level
- RNXT $1.15
- IGC $0.43
- Average True Range (ATR)
- RNXT 0.09
- IGC 0.02
- MACD
- RNXT -0.01
- IGC -0.00
- Stochastic Oscillator
- RNXT 39.99
- IGC 47.05
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.